Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Enterprise ValueMarket Capitalization

RAPT Therapeutics (RAPT) EBIT Margin: 2020-2022

Historic EBIT Margin for Therapeutics (RAPT) over the last 2 years, with Jun 2022 value amounting to -2,134.20%.

  • Therapeutics' EBIT Margin fell 28368.00% to -2,134.20% in Q2 2022 from the same period last year, while for Jun 2022 it was -2,346.97%, marking a year-over-year decrease of 112145.00%. This contributed to the annual value of -5,618.53% for FY2022, which is 380345.00% down from last year.
  • Latest data reveals that Therapeutics reported EBIT Margin of -2,134.20% as of Q2 2022, which was up 34.16% from -3,241.34% recorded in Q1 2022.
  • Therapeutics' 5-year EBIT Margin high stood at -954.25% for Q3 2020, and its period low was -3,241.34% during Q1 2022.
  • In the last 3 years, Therapeutics' EBIT Margin had a median value of -1,622.42% in 2021 and averaged -1,721.86%.
  • In the last 5 years, Therapeutics' EBIT Margin surged by 3,909bps in 2021 and then plummeted by 188,610bps in 2022.
  • Therapeutics' EBIT Margin (Quarterly) stood at -1,004.99% in 2020, then slumped by 138,046bps to -2,385.45% in 2021, then slumped by 28,368bps to -2,134.20% in 2022.
  • Its EBIT Margin was -2,134.20% in Q2 2022, compared to -3,241.34% in Q1 2022 and -2,385.45% in Q4 2021.